KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) Equity Average (2017 - 2026)

Cardlytics filings provide 10 years of Equity Average readings, the most recent being -$5.3 million for Q1 2026.

  • Quarterly Equity Average fell 107.84% to -$5.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Mar 2026, down 107.84% year-over-year, with the annual reading at $31.7 million for FY2025, 69.0% down from the prior year.
  • Equity Average hit -$5.3 million in Q1 2026 for Cardlytics, up from -$5.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $701.2 million in Q1 2022 and bottomed at -$5.6 million in Q4 2025.
  • Average Equity Average over 5 years is $229.4 million, with a median of $180.1 million recorded in 2023.
  • The largest annual shift saw Equity Average surged 55.46% in 2022 before it crashed 108.03% in 2025.
  • Cardlytics' Equity Average stood at $396.1 million in 2022, then plummeted by 54.54% to $180.1 million in 2023, then tumbled by 61.21% to $69.8 million in 2024, then tumbled by 108.03% to -$5.6 million in 2025, then rose by 6.25% to -$5.3 million in 2026.
  • Per Business Quant, the three most recent readings for CDLX's Equity Average are -$5.3 million (Q1 2026), -$5.6 million (Q4 2025), and $27.0 million (Q3 2025).